Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.
Distant metastases and drug resistance account for poor survival of patients with gastrointestinal (GI) malignancies such as gastric cancer, pancreatic cancer, and colorectal cancer.
APA
Dong D, Yu X, et al. (2024). Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 77, 101125. https://doi.org/10.1016/j.drup.2024.101125
MLA
Dong D, et al.. "Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 77, 2024, pp. 101125.
PMID
39173439
Abstract
Distant metastases and drug resistance account for poor survival of patients with gastrointestinal (GI) malignancies such as gastric cancer, pancreatic cancer, and colorectal cancer. GI cancers most commonly metastasize to the liver, which provides a unique immunosuppressive tumour microenvironment to support the development of a premetastatic niche for tumor cell colonization and metastatic outgrowth. Metastatic tumors often exhibit greater resistance to drugs than primary tumors, posing extra challenges in treatment. The liver metastases and drug resistance of GI cancers are regulated by complex, intertwined, and tumor-dependent cellular and molecular mechanisms that influence tumor cell behavior (e.g. epithelial-to-mesenchymal transition, or EMT), tumor microenvironment (TME) (e.g. the extracellular matrix, cancer-associated fibroblasts, and tumor-infiltrating immune cells), tumor cell-TME interactions (e.g. through cytokines and exosomes), liver microenvironment (e.g. hepatic stellate cells and macrophages), and the route and mechanism of tumor cell dissemination (e.g. circulating tumor cells). This review provides an overview of recent advances in the research on cellular and molecular mechanisms that regulate liver metastases and drug resistance of GI cancers. We also discuss recent advances in the development of mechanism-based therapy for these GI cancers. Targeting these cellular and molecular mechanisms, either alone or in combination, may potentially provide novel approaches to treat metastatic GI malignancies.
MeSH Terms
Humans; Drug Resistance, Neoplasm; Tumor Microenvironment; Liver Neoplasms; Gastrointestinal Neoplasms; Epithelial-Mesenchymal Transition; Antineoplastic Agents; Animals; Neoplastic Cells, Circulating
같은 제1저자의 인용 많은 논문 (4)
- Integrative analysis reveals prognostic value of cuproptosis and copper hemostasis related genes in immunotherapy for non-small cell lung cancer.
- Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.
- Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies.
- STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer.